METHODOLOGY
Type of study - Randomised controlled trial (RCT)
Study period - March 2014 to July 2016
Place of study - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi
Study group - Bronchiectasis that is not attributable to Cystic fibrosis
* Group 1 - Pulmonary Rehabilitation (PR)
* Group 2 - Standard care
Sample size - 20 in each arm
The study requires patients to attend the pulmonary rehabilitation program twice a week for 8 weeks.
Consent will be taken from all patients prior to enrollment.
Exacerbations of bronchiectasis will be defined by the following criteria:
At least four of the following clinical signs and symptoms suggestive of an acute exacerbation of bronchiectasis over two consecutive days:
* Increase in sputum quantity
* Change in sputum colour
* Change in sputum viscosity
* Increase in cough
* Increase in dyspnoea
* Increase in fatigue/lethargy
* Fever (self-reported)
* Episode of haemoptysis
The number of acute pulmonary exacerbations per year in the previous years will be recorded.
All patients attending the out patient department of pulmonary department of All India Institute of Medical Sciences will be screened for recruitment in the study.
Baseline evaluation
All patients who qualify for the study will undergo a detailed evaluation. This will include demographic data, complete medical history and clinical examination including anthropometry. Baseline assessment will include the following parameters:
i. Anthropometry
ii. Pulmonary Function Tests and Respiratory muscle strength
iii. Cardiopulmonary Exercise Testing (CPET)
iv. Six Minute Walk Test (6MWT)
v. Severity of dyspnoea (Dyspnoea scale)
vi. Limb muscle strength
vii. Inflammatory markers in the serum - C-reactive protein
viii. Quality of Life
The participants will then be randomly assigned to receive either standard care alone or pulmonary rehabilitation. The randomisation will be completed by the creation of a random numbers table.
Intervention
Standard care group
Candidates randomized to the "standard care group" will receive standard care for bronchiectasis according to current guidelines. These participants will receive instruction and review of airway clearance therapy (ACT). Each participant will be provided with written information about bronchiectasis and education regarding self-management of the condition. Participants who have not been previously instructed in any ACT will be taught the active cycle of breathing technique. These participants will not receive any supervised exercise training.
Pulmonary rehabilitation group
Participants randomised to the Pulmonary Rehabilitation group will receive exercise training and regular instruction in self-management of ACT along with standard care. Patients will be enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine and Sleep disorders, All India Institute of Medical Sciences.
The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one will be at home. The patient will be asked to maintain a personal log recording the date, time, duration and type of exercise performed to ensure compliance, and these will be regularly reviewed and monitored.
The Rehabilitation Programme will include the following:
i. Patient education
ii. Exercise training
iii. Ventilator and breathing exercises
Outcome Assessment
The patients will be reassessed at the end of the 8 week training programme.
Primary outcome measures:
* Maximum exercise capacity - measured with the 6MWT (the primary outcome is the greatest distance walked) and the CPET (VO2 max)
* HRQoL measured with the St. George Respiratory Questionnaire
Secondary outcome measures:
* Change in the Leicester Cough Questionnaire
* Change in the C- reactive protein
* Change in the lung Functions
* Change in the anxiety and depressions score
* Change in the hand grip dynamometry
